Clinical trial
Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy…
NCT00391248 · Ontario Clinical Oncology Group (OCOG), Other · Completed
Key facts
| NCT number | NCT00391248 |
|---|---|
| Title | Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL) |
| Official title | A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Patients With Non-small Cell Carcinoma of the Lung. (PEARL Trial) |
| Lead sponsor | Ontario Clinical Oncology Group (OCOG), Other |
| Collaborators | Roche Pharma AG Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Erlotinib |
| Enrollment | 40 |
| Start date | Nov 1, 2006 |
| Primary completion | Dec 1, 2012 |
| Completion | Dec 1, 2012 |
| First posted | Oct 23, 2006 |
| Last update posted | Jan 29, 2013 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: